Walleye Capital’s Aquestive Therapeutics AQST Stock Holding History

Walleye Capital’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.43M	Buy	584,977 +297,166	+103%	+$1.21M	0.01%	1323
2025 Q4	$1.86M	Sell	287,811 -217,463	-43%	-$1.36M	0.01%	1937
2025 Q3	$2.82M	Buy	505,274 +267,370	+112%	+$1.16M	0.01%	1330
2025 Q2	$787K	Buy	237,904 +198,323	+501%	+$569K	﹤0.01%	2245
2025 Q1	$115K	Buy	+39,581	New	+$120K	﹤0.01%	3563
2024 Q3	–	Sell	-26,892	Closed	-$69.9K	–	5242
2024 Q2	$69.9K	Sell	26,892 -23,543	-47%	-$78.6K	﹤0.01%	4840
2024 Q1	$215K	Sell	50,435 -75,781	-60%	-$252K	﹤0.01%	3933
2023 Q4	$255K	Sell	126,216 -29,372	-19%	-$51.9K	﹤0.01%	3499
2023 Q3	$238K	Sell	155,588 -248,310	-61%	-$427K	﹤0.01%	3418
2023 Q2	$666K	Buy	+403,898	New	+$731K	﹤0.01%	2210

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Walleye Capital's AQST Position: Q1 2026 in Review

Walleye Capital increased its Aquestive Therapeutics (AQST) stake by 103% in Q1 2026, buying an estimated $1.21M and bringing the position to 584,977 shares worth $2.43M. The position accounts for 0.01% of the portfolio, ranked #1323.

Walleye Capital first reported a position in AQST in Q2 2023 and has held it in 10 quarters since. The position peaked at $2.82M in Q3 2025. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

Walleye Capital held 584,977 shares of Aquestive Therapeutics worth $2.43M as of Q1 2026.
Walleye Capital bought 297,166 Aquestive Therapeutics shares in Q1 2026, an estimated $1.21M.
Aquestive Therapeutics made up 0.01% of Walleye Capital's portfolio in Q1 2026, its #1323 holding.
Walleye Capital first reported a position in Aquestive Therapeutics in Q2 2023 and has held it in 10 quarters since.
Walleye Capital's Aquestive Therapeutics position peaked at $2.82M in Q3 2025.
179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.